SCHEMBL4470860

SCHEMBL4470860

CC(C)(C)OC(=O)NC1CN(c2ccc(C(F)(F)F)cn2)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 2/20 0.53
KMT2A Q03164 2/20 0.51
MAPT P10636 2/20 0.50
ALDH1A1 P00352 1/20 0.50
HSD11B1 P28845 1/20 0.50
ACACB O00763 2/20 0.49
HCRTR1 O43613 2/20 0.49
HCRTR2 O43614 2/20 0.49
MEN1 O00255 1/20 0.49
HRH3 Q9Y5N1 1/20 0.49
KDM4E B2RXH2 3/20 0.49
PDE10A Q9Y233 1/20 0.48
TRPV1 Q8NER1 3/20 0.48
TRPM8 Q7Z2W7 1/20 0.48
HPGD P15428 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
ABL1 P00519 1/20 0.48
LMNA P02545 1/20 0.48
POLB P06746 1/20 0.47
CA12 O43570 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1351078 0.91 SYK (0.63) SYKKMT2AHSD11B1MEN1HRH3
SCHEMBL1351080 0.91 SYK (0.63) SYKKMT2AHSD11B1MEN1HRH3
SCHEMBL24630475 0.89 HSD11B1 (0.58) SYKKMT2AMAPTALDH1A1HSD11B1
SCHEMBL29773191 0.89 HSD11B1 (0.58) SYKKMT2AMAPTALDH1A1HSD11B1
SCHEMBL19754737 0.84 CHRM4 (0.49) SYKACACBPDE10A
SCHEMBL31410428 0.84 HSD11B1 (0.55) KMT2AMAPTALDH1A1HSD11B1MEN1
SCHEMBL29007869 0.83 MAP4K4 (0.51) SYKPDE10A
SCHEMBL30181322 0.83 MAP4K4 (0.51) SYKPDE10A
SCHEMBL31370459 0.83 PDE10A (0.50) SYKACACBPDE10A
SCHEMBL66173 0.83 HCRTR1 (0.48) SYKKMT2AMAPTALDH1A1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514562-B2 Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain GLAXO GROUP LIMITED (GB) 2009-04-07 US disclosed
US-20060276447-A1 Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain GLAXO GROUP LIMITED (GB) 2006-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276447-A1 Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain TRPV1, UTS2R, OPRL1 SYK 3457/4885KMT2A 3515/4885MAPT 2006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.